A group of leading doctors from across Brazil gathered in San Diego today to attend a symposium on the medicinal benefits of cannabis use.
The three-day conference is hosted by Medical Marijuana Inc. (OTC: MJNA) and it runs until May 1. The company has a subsidiary called HempMeds Brasil and it organized the symposium for the doctors.
They will visit the Medical Marijuana Inc. headquarters and the TERI Campus of Life, a non-profit centre of innovation and social change for children and adults touched by special needs. The aim is to educate the doctors about the therapeutic benefits marijuana can offer anyone suffering from autism and epilepsy.
The idea is that these medical experts will then go back to Brazil, the largest economy in Latin America and the ninth largest economy in the world, and spread the gospel to patients, medical groups and fellow doctors.
“Over the past few years, we have enthusiastically offered events like this one to doctors from all over the world so that we can be the leading charge to help dispel the many myths and misconceptions about cannabis and CBD,” said Medical Marijuana Inc. chief executive Dr. Stuart Titus.
Caroline Heinz, the vice president of HempMeds Brasil added that they hope to forge long-lasting relationships and work together to expand CBD access to patients in Brazil.
Medical Marijuana Inc. is a specialist CBD producer that should expect to benefit from the passage of the 2018 Farm Bill. But it is also keen to expand across the globe and it has operations in Mexico and Brazil.
Medicinal marijuana has been legal in Brazil since 2017 and last year its social affairs committee – Comissao de Assuntos Sociais – approved a bill to authorize home growing of medical cannabis.
The industry has been slow to get off the ground there, but many see it as an important new frontier. Australian producer Creso Pharma (ASX: CHP) recently won a license to import into Brazil and it plans to target Sao Paulo, Rio de Janeiro, and Curitiba. It believes oncologists and neurologists in those three cities have more than 50,000 patients that it can serve.
There are 209 million people in Brazil. It previously only authorized Sativex as the sole medical CBS product, but the government has now approved cannaQIX 50, a product that helps patients with neuropathic and cancer-related pain. Creso’s expansion into Brazil is in partnership with SIN Solution.
About Author
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Grizzle hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.